<DOC>
	<DOCNO>NCT00441727</DOCNO>
	<brief_summary>The purpose study compare effect esomeprazole 20 40 mg daily versus placebo occurrence peptic ulcer 26 week subject continuous low-dose acetylsalicylic acid .</brief_summary>
	<brief_title>Study Esomeprazole 20 mg 40 mg v Placebo Effectiveness Occurrence Peptic Ulcers Subjects Low Dose Acetylsalicylic Acid ( LDA )</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Peptic Ulcer</mesh_term>
	<mesh_term>Duodenal Ulcer</mesh_term>
	<mesh_term>Stomach Ulcer</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Esomeprazole</mesh_term>
	<criteria>Daily intake lowdose Aspirin ( ASA ) The subject must fulfill least one follow ( ae ) : Aged ≥65 year . Aged ≥18 year document history uncomplicated peptic ulcer ( ) . Aged ≥60 year naïve lowdose ASA ( ie , treatment start within 1 month prior randomization ) . Aged ≥60 year stable coronary artery disease . Aged ≥60 year complaints upper gastrointestinal ( GI ) symptom , judge investigator , require Esophagogastroduodenoscopy ( EGD ) find ≥5 gastric and/or duodenal erosion baseline endoscopy . Peptic ulcer ( ) baseline esophagogastroduodenoscopy ( EGD ) . Reflux esophagitis Los Angeles ( LA ) classification grade C D baseline History peptic ulcer complication clinically significant bleed and/or perforation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Peptic ulcer</keyword>
	<keyword>low-dose ASA</keyword>
</DOC>